There are no virological or clinical benefits to giving double doses of the drug oseltamivir to patients with influenza, according to a study published online by bmj.com.
Researchers at the South East Asian Infectious Disease Clinical Research Network studied 326 patients who received either standard dose oseltamivir (75 mg twice a day or children's equivalent) or double dose (150 mg twice a day or children's equivalent) for five days.
The researchers found no differences between the groups in virus levels, deaths or rates of adverse events between the different doses.